Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

XLO Xilio Therapeutics Inc

0,9555

-0,0145 (-1,49%)

01 Jan 2025 - Geschlossen

Verzögert um 15 Minuten

Form 3 - Initial statement of beneficial ownership of securities

Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more Xilio Therapeutics Charts.

Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more Xilio Therapeutics Charts.

News Xilio Therapeutics Inc

Form 8-K - Current report
Donnerstag 19 Dezember 2024 (2 Wochen vor) • Edgar (US Regulatory)

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
Donnerstag 19 Dezember 2024 (2 Wochen vor) • GlobeNewswire Inc.

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer
Montag 16 Dezember 2024 (2 Wochen vor) • GlobeNewswire Inc.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dienstag 3 Dezember 2024 (4 Wochen vor) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Donnerstag 7 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 7 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Donnerstag 7 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
Donnerstag 7 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Mittwoch 30 Oktober 2024 (2 Monate vor) • GlobeNewswire Inc.

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Freitag 4 Oktober 2024 (3 Monate vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 2 Oktober 2024 (3 Monate vor) • Edgar (US Regulatory)

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mittwoch 2 Oktober 2024 (3 Monate vor) • GlobeNewswire Inc.

Weitere Xilio Therapeutics Inc News-Artikel

JP Morgan Chase

Deutsche Telekom

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen